HS Pharma is focused on the development of novel therapeutics centered on a family of non-toxic, silicate-based molecules that facilitate the body’s immune system to attack cancer and cancerous cells while also promoting dramatic healing of complex/infected wounds and burns.
HS-7, our IV-administered new drug candidate, contains a precisely-tailored form of silica that rapidly elicits immune-adjuvant activity, but is then resorbed into benign (e.g. essential) metabolites for side-effect free therapy; from a patient cost perspective, we have the ability to deliver a significantly more affordable treatment option.
Complex/Infected Wounds & Burns
HS-X, our innovative topically-administered new drug candidate, has the unique ability to promote the rapid healing of complex/infected wounds and burns while also dramatically minimizing scar formation. The HS-X ointment activates a localized immune response to the wounds site, clears foreign pathogens and rapidly accelerates healing.